BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 15780430)

  • 1. The physiological role of GLP-1 in human: incretin, ileal brake or more?
    Schirra J; Göke B
    Regul Pept; 2005 Jun; 128(2):109-15. PubMed ID: 15780430
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical endocrinology and metabolism. Glucagon-like peptide-1 and glucagon-like peptide-2.
    Baggio LL; Drucker DJ
    Best Pract Res Clin Endocrinol Metab; 2004 Dec; 18(4):531-54. PubMed ID: 15533774
    [TBL] [Abstract][Full Text] [Related]  

  • 3. What do we know about the secretion and degradation of incretin hormones?
    Deacon CF
    Regul Pept; 2005 Jun; 128(2):117-24. PubMed ID: 15780431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glucagon-like peptide 1: evolution of an incretin into a treatment for diabetes.
    D'Alessio DA; Vahl TP
    Am J Physiol Endocrinol Metab; 2004 Jun; 286(6):E882-90. PubMed ID: 15140755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is glucagon-like peptide 1 an incretin hormone?
    Nauck MA
    Diabetologia; 1999 Mar; 42(3):373-9. PubMed ID: 10096792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glucagon-like peptide 1(GLP-1) in biology and pathology.
    Meier JJ; Nauck MA
    Diabetes Metab Res Rev; 2005; 21(2):91-117. PubMed ID: 15759282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glucagon-like peptide-1 secretion is influenced by perfusate glucose concentration and by a feedback mechanism involving somatostatin in isolated perfused porcine ileum.
    Hansen L; Hartmann B; Mineo H; Holst JJ
    Regul Pept; 2004 Apr; 118(1-2):11-8. PubMed ID: 14759551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Glucagon-like peptides--synthesis, biological actions and some clinical implications].
    Otto Buczkowska E; Dworzecki T
    Przegl Lek; 2004; 61(9):947-50. PubMed ID: 15803906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GLP-1 and extra-islet effects.
    Ahrén B
    Horm Metab Res; 2004; 36(11-12):842-5. PubMed ID: 15655717
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glucagon-like peptide-1 (7-36) amide: a central regulator of satiety and interoceptive stress.
    van Dijk G; Thiele TE
    Neuropeptides; 1999 Oct; 33(5):406-14. PubMed ID: 10657518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enteroglucagon.
    Holst JJ
    Annu Rev Physiol; 1997; 59():257-71. PubMed ID: 9074764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glucagon-like peptide 1 (GLP-1) in the treatment of diabetes.
    Nauck MA
    Horm Metab Res; 2004; 36(11-12):852-8. PubMed ID: 15655719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biologic actions and therapeutic potential of the proglucagon-derived peptides.
    Drucker DJ
    Nat Clin Pract Endocrinol Metab; 2005 Nov; 1(1):22-31. PubMed ID: 16929363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. alpha-Glucosidase inhibition (acarbose) fails to enhance secretion of glucagon-like peptide 1 (7-36 amide) and to delay gastric emptying in Type 2 diabetic patients.
    Hücking K; Kostic Z; Pox C; Ritzel R; Holst JJ; Schmiegel W; Nauck MA
    Diabet Med; 2005 Apr; 22(4):470-6. PubMed ID: 15787675
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The intestinal hormone glucagon-like peptide 1 (GLP-1): from experiment to the clinic].
    Göke B; Fehmann HC; Schirra J; Hareter A; Göke R
    Z Gastroenterol; 1997 Apr; 35(4):285-94. PubMed ID: 9221612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential effects of subcutaneous GLP-1 on gastric emptying, antroduodenal motility, and pancreatic function in men.
    Schirra J; Kuwert P; Wank U; Leicht P; Arnold R; Göke B; Katschinski M
    Proc Assoc Am Physicians; 1997 Jan; 109(1):84-97. PubMed ID: 9010920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glycaemic effects of incretins in Type 1 diabetes mellitus: a concise review, with emphasis on studies in humans.
    Dupre J
    Regul Pept; 2005 Jun; 128(2):149-57. PubMed ID: 15780434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extrapancreatic effects of GIP and GLP-1.
    Vella A; Rizza RA
    Horm Metab Res; 2004; 36(11-12):830-6. PubMed ID: 15655715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glucagon-like peptide 1 agonists and the development and growth of pancreatic beta-cells.
    List JF; Habener JF
    Am J Physiol Endocrinol Metab; 2004 Jun; 286(6):E875-81. PubMed ID: 15140754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neural regulation of glucagon-like peptide-1 secretion in pigs.
    Hansen L; Lampert S; Mineo H; Holst JJ
    Am J Physiol Endocrinol Metab; 2004 Nov; 287(5):E939-47. PubMed ID: 15475512
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.